GW Pharmaceuticals Regains Commercialization Rights to Sativex
GW Pharmaceuticals and Bayer have revealed that GW will regain the exclusive commercialization rights for Sativex (delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]) in the UK.
GW Pharmaceuticals and Bayer have revealed, in a March 2, 2020 press release, that GW will regain the exclusive commercialization rights for Sativex (delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]) in the United Kingdom.
Under the terms of the agreement, a transitional period will be in place until Dec. 31, 2020, after which point, GW will assume all responsibilities for Sativex (known by the USAN name nabiximols) in the UK. Since the approval of Sativex, Bayer has been responsible for all marketing in the country.
During the transition period, the companies will work together closely to ensure a seamless changeover for healthcare professionals and patients. There is no change to the day-to-day business practices for now, and stakeholders will receive further notification when transfers and operations are anticipated.
Source: GW Pharmaceuticals
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
